公开(公告)号：US20180086716A1

公开(公告)日：2018-03-29

申请号：US15711984

申请日：2017-09-21

Applicant: NOVARTIS AG

Inventor： Badry BURSULAYA ,  Andreas FISCH ,  James Paul LAJINESS ,  Rainer MACHAUER ,  Swapnil MALEKAR ,  Hank Michael James PETRASSI ,  Farshad RAMAZANI ,  Anne-Catherine REMOND ,  Thomas ULLRICH ,  Peggy USSELMANN ,  Eric VANGREVELINGHE

IPC: C07D231/56 ,  A61K9/16 ,  A61K9/00 ,  C07D403/12 ,  A61K31/416 ,  C07D401/12 ,  A61K31/454 ,  C07D405/12

CPC classification number: C07D231/56 ,  A61K9/0019 ,  A61K9/1647 ,  A61K31/416 ,  A61K31/454 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12

Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20220251067A1

公开(公告)日：2022-08-11

申请号：US17574820

申请日：2022-01-13

Applicant: Novartis AG

Inventor： Christopher FARADY ,  Nina GOMMERMANN ,  Philipp JANSER ,  Angela MACKAY ,  Henri MATTES ,  Nichola SMITH ,  Catherine Fooks SOLOVAY ,  Nikolaus Johannes STIEFL ,  Eric VANGREVELINGHE ,  Juraj VELCICKY ,  Anette von MATT

IPC: C07D401/12 ,  C07D237/14 ,  C07D237/20 ,  C07D403/12 ,  C07D413/12 ,  C07D451/04

Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.

公开(公告)号：US20210188842A1

公开(公告)日：2021-06-24

申请号：US16941395

申请日：2020-07-28

Applicant: NOVARTIS AG

Inventor： Badry BURSULAYA ,  Andreas FISCH ,  James Paul LAJINESS ,  Rainer MACHAUER ,  Swapnil MALEKAR ,  Hank Michael James PETRASSI ,  Farshad RAMAZANI ,  Anne-Catherine REMOND ,  Thomas ULLRICH ,  Peggy USSELMANN ,  Eric VANGREVELINGHE

IPC: C07D471/04 ,  A61P21/00 ,  A61K9/00 ,  A61K9/50 ,  A61K31/437 ,  A61K31/496 ,  A61K31/538

Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20190300522A1

公开(公告)日：2019-10-03

申请号：US16335496

申请日：2017-09-21

Applicant: NOVARTIS AG

Inventor： Badry BURSULAYA ,  Andreas FISCH ,  James Paul LAJINESS ,  Rainer MACHAUER ,  Swapnil MALEKAR ,  Hank Michael James PETRASSI ,  Farshad RAMAZANI ,  Anne-Catherine REMOND ,  Thomas ULLRICH ,  Peggy USSELMANN ,  Eric VANGREVELINGHE

IPC: C07D471/04 ,  A61K9/00 ,  A61K9/50 ,  A61P21/00 ,  A61K31/437 ,  A61K31/538 ,  A61K31/496

Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.